Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 11291667 Combination therapy involving diaryl macrocyclic compounds

Patent 11291667 was granted and assigned to Turning Point Therapeutics on April, 2022 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributorsActivity

All edits

Edits on 4 Apr, 2024
"update inverses"
Golden AI profile picture
Golden AI
edited on 4 Apr, 2024
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
‌
US Patent 11945785 Pyrazine compounds as inhibitors of FLT3
0
Edits on 23 May, 2023
"Remove website redirecting to Patent Public Search front page"
Golden AI profile picture
Golden AI
edited on 23 May, 2023
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
https://pdfpiw.uspto.gov/.piw?Docid=1129166700
Edits on 27 Apr, 2023
"update citations for inverse infoboxes"
Golden AI profile picture
Golden AI
edited on 27 Apr, 2023
Edits on 25 Mar, 2023
"Entity importer update"
Golden AI profile picture
Golden AI
edited on 25 Mar, 2023
Edits on 26 Sep, 2022
"Entity importer update"
Golden AI profile picture
Golden AI
edited on 26 Sep, 2022
Edits on 25 Sep, 2022
"update citations for inverse infoboxes"
Golden AI profile picture
Golden AI
edited on 25 Sep, 2022
Edits on 6 Jun, 2022
"Entity importer update"
Golden AI profile picture
Golden AI
edited on 6 Jun, 2022
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
https://pdfpiw.uspto.gov/.piw?Docid=11291667
Edits on 6 Apr, 2022
"Created via: Entity Importer"
Golden AI profile picture
Golden AI
created this topic on 6 Apr, 2022
Edits made to:
Infobox (+20 properties)
Article (+189 characters)
‌

 US Patent 11291667 Combination therapy involving diaryl macrocyclic compounds

Article

The present disclosure relates to methods and compositions for treating cancer with a diaryl macrocycle in combination with at least one other cancer therapeutic, such as an EGFR inhibitor.

Infobox
Is a
Patent
Patent
Patent applicant
Turning Point Therapeutics
Turning Point Therapeutics
Current assignee
Turning Point Therapeutics
Turning Point Therapeutics
Patent jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent number
11291667
Date of patent
April 5, 2022
Patent application number
16480557
Date Filed
January 25, 2018
Patent citations
‌
US Patent 10246466 Diaryl macrocycles as modulators of protein kinases
‌
US Patent 10316044 Chiral diaryl macrocycles as modulators of protein kinases
‌
US Patent 10294242 Diaryl macrocycle polymorph
Patent primary examiner
‌
Julie Wu
CPC Code
‌
C07D 498/18
‌
A61K 45/06
‌
A61K 39/3955
‌
A61P 35/00
‌
A61K 31/5377
‌
A61K 31/519
‌
A61K 31/517
‌
A61K 31/506

Find more entities like US Patent 11291667 Combination therapy involving diaryl macrocyclic compounds

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
By using this site, you agree to our Terms of Service.